To sustain the growth trajectories that biotech shareholders have come to expect, large biotech companies today rely increasingly on smaller biotech companies to build their pipelines. Competition among biotech and pharmaceutical companies for high-quality products drives price escalation and fuels innovative thinking regarding deal approaches and structures.



Objectives:

Outline how large biotech companies strive to differentiate themselves in the drive for externally sourced growth.

Discuss whether the dynamics of the deal process can distinguish bidders from their competitors.

Discuss whether any partnering and acquisition innovations truly help large biotech companies win the deal while preserving the upside potential.